Johnson & Johnson JNJ

$263.81 -3.80 (-1.42%)

Valuation

Market cap
635,072,512,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
25.13
Forward PE
24.07
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,309,100
Avg volume
6,964,168
Day's range
$262.40 – $266.03
Shares out
2,407,310,000
Stochastic %K
76%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

No headlines yet.

Stocktwits

TopOptionAlert Oct 25, 2:33 AM
$JNJ NOV20 270C · actionable here Zone: $261.96 to $265.66 Invalidation: close under $259.04 Objectives: $269.67, then $281.07 The math: up 2.2% to the first objective and 6.5% to the second, against 1.8% risk on the invalidation, better than 3 to 1 to the second. Dear friend, think of a steady shop that gave back a little on Friday after a strong Thursday, then woke up Saturday to good news about its prostate treatment cutting recurrence risk by 62 percent in a big trial. This is a swing, and the simple read is that Friday was a pause while buyers caught their breath, not a turn, because price still sits above the 259 dollar floor from Thursday. If that floor holds, the path back toward the Thursday high and then toward the high for the year near 281 dollars is open, and a close under that floor tells you the jump has faded and it is time to step aside. P.S. The next earnings report sits in January, after this contract expires, so this swing is judged on price and trial news, not on a report.
0 replies
BioTechHealthX Oct 25, 2:28 AM
$JNJ Johnson & Johnson raised its annual sales outlook to a $101.2 billion midpoint, but quarterly adjusted EPS fell 7.5%. Explore the growth drivers and earnings pressure. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-eyes-101-2-billion-in-annual-sales/
0 replies
BioTechHealthX Oct 25, 2:05 AM
$AMGN $NVS $AZN $JNJ $LLY Inflation keeps investors guessing, but healthcare demand endures. Explore five profitable healthcare stocks with low beta and market values above $200 billion. https://biotechhealthx.com/biotech-news/5-no-brainer-healthcare-stocks-to-buy-now/
0 replies
Monn1985 Oct 24, 6:32 PM
$MRNA Such a scam company with their failed Covid vaccines as well! J&J or other great American companies should have taken the lead but not this scam! $JNJ
0 replies
chursinow62 Oct 24, 4:54 PM
$JNJ This is going to pop on Monday with new cancer drug positive results for prostate cancer shrinkage
1 replies
focafoca99 Oct 24, 1:05 PM
$JNJ reported a 62% lower risk of recurrence or death with apalutamide plus ADT versus surgery alone in prostate cancer. https://www.rapidticker.com/news/jnj-johnson-johnson-announces-erleada-apalutamide-7d45cd
1 replies
flychicken1991 Oct 24, 1:00 PM
$JNJ Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer. Impact: Positive (84%). shares could receive modest upward support as stronger evidence for an additional ERLEADA indication increases the perceived value of future drug sales; the announcement establishes no immediate earnings increase. Source and what to watch next: https://nimpact.tech/newsimpact/news/ae16257df6eb8ecb/jnj-johnson-johnson-announces-erleada-apalutamide-treatment-before-and-a?utm_source=stocktwits&utm_medium=story_url
0 replies
Rayvio_News_Filter Oct 24, 12:56 PM
$JNJ 🏥 Johnson & Johnson announced Phase 3 PROTEUS substudy results showing perioperative apalutamide plus ADT for six months before and after surgery reduced risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer, with 51% lower estimated risk of metastasis or death and twice as many patients free from subsequent treatment at three years. Curated for market relevance
0 replies